The mortality rate after hospital discharge in patients with myelomeningocele decreased after implementation of mandatory flour fortification with folic acid;Redução da taxa de mortalidade após a alta hospitalar em pacientes com mielomeningocele depois da implementação da fortificação obrigatória das farinhas com ácido fólico

Arquivos de Neuro-Psiquiatria

Volumn 75, Issue 1, 2017, Pages 20-24

  Salomão, Renato Manganelli ^a   Cervante, Tatiana Protzenko ^b   Salomão, José Francisco Manganelli ^b   Leon, Soniza Vieira Alves ^a  

^a FEDERAL UNIVERSITY OF THE STATE OF RIO DE JANEIRO   (Brazil)

^b INSTITUTO OSWALDO CRUZ   (Brazil)

Author keywords

Folic acid; Meningomyelocele; Mortality

Indexed keywords

FOLIC ACID; VITAMIN B COMPLEX;

ARNOLD CHIARI MALFORMATION; ARTICLE; BIOFORTIFICATION; BRAIN VENTRICLE PERITONEUM SHUNT; CAUSE OF DEATH; CENTRAL NERVOUS SYSTEM INFECTION; CEREBROSPINAL FLUID INFECTION; COHORT ANALYSIS; COMORBIDITY ASSESSMENT; DEATH; FEMALE; FETUS RISK; FLOUR; HOSPITAL DISCHARGE; HUMAN; INFANT; INTRACRANIAL HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MENINGOMYELOCELE; MORTALITY RATE; RESPIRATORY TRACT INFECTION; RETROSPECTIVE STUDY; RISK FACTOR; SEPSIS; SHUNT INFECTION; VENTRICULOPERITONEAL SHUNT MALFUNCTION; VENTRICULOPERITONEAL SHUNT SHORTENING; WOUND INFECTION; CHILD; DIET THERAPY; FORTIFIED FOOD; MORTALITY; PRESCHOOL CHILD;

CAUSE OF DEATH; CHILD; CHILD, PRESCHOOL; FEMALE; FLOUR; FOLIC ACID; FOOD, FORTIFIED; HUMANS; INFANT; MENINGOMYELOCELE; PATIENT DISCHARGE; RETROSPECTIVE STUDIES; RISK FACTORS; VITAMIN B COMPLEX;

EID: 85009997706     PISSN: 0004282X     EISSN: 16784227     Source Type: Journal    
DOI: 10.1590/0004-282x20160184     Document Type: Article

References (31)

1. Padmanabhan R. Etiology, pathogenesis and prevention of neural tube defects. Congenit Anom (Kyoto). 2006; 46 (2): 55-67. doi: 10.1111/j.1741-4520.2006.00104.x
2. Blencowe H, Cousens S, Modell B, Lawn J. Folic acid to reduce neonatal mortality from neural tube disorders. Int J Epidemiol. 2010; 39 Suppl 1: i110-21. doi: 10.1093/ije/dyq028
3. Adzick NS. Fetal myelomeningocele: natural history, pathophysiology, and in-utero intervention. Semin Fetal Neonatal Med. 2010; 15 (1): 9-14. doi: 10.1016/j.siny.2009.05.002
4. Busby A, Abramsky L, Dolk H, Armstrong B. Preventing neural tube defects in Europe: population based study. BMJ. 2005; 330 (7491): 574-58. doi: 10.1136/bmj.330.7491.574
5. De Marco P, Merello E, Calevo MG, Mascelli S, Pastorino D, Crocetti L, et al. Maternal periconceptional factors affect the risk of spina bifida-affected pregnancies: an Italian case-control study. Childs Nerv Syst. 2011; 27 (7): 1073-81. doi: 10.1007/s00381-010-1372-y
6. Orioli IM, Lima do Nascimento R, López-Camelo JS, Castilla EE. Effects of folic acid fortification on spina bifida prevalence in Brazil. Birth Defects Res A Clin Mol Teratol. 2011; 91 (9): 831-5. doi: 10.1002/bdra.20830
7. Schuler-Faccini L, Sanseverino MTV, de Rocha Azevedo LM, Moorthie S, Alberg C, Chowdhury S, et al. Health needs assessment for congenital anomalies in middle-income countries: examining the case for neural tube defects in Brazil. J Community Genet. 2014; 5 (2): 147-55. doi: 10.1007/s12687-013-0165-x
8. Sandler AD. Children with spina bifida: key clinical issues. Pediatr Clin North Am. 2010; 57 (4): 879-92. doi: 10.1016/j.pcl.2010.07.009
9. Oakeshott P, Hunt GM. Long-term outcome in open spina bifida. Br J Gen Pract. 2003; 53 (493): 632-6.
10. Woodhouse CRJ. Myelomeningocele: neglected aspects. Pediatr Nephrol. 2008; 23 (8): 1223-31. doi: 10.1007/s00467-007-0663-3
11. Bol KA, Collins JS, Kirby RS, National Birth Defects Prevention Network. Survival of infants with neural tube defects in the presence of folic acid fortification. Pediatrics. 2006; 117 (3): 803-13. doi: 10.1542/peds.2005-1364
12. Sayed AR, Bourne D, Pattinson R, Nixon J, Henderson B. Decline in the prevalence of neural tube defects following folic acid fortification and its cost-benefit in South Africa. Birth Defects Res A Clin Mol Teratol. 2008; 82 (4): 211-6. doi: 10.1002/bdra.20442
13. López-Camelo JS, Castilla EE, Orioli IM. Folic acid flour fortification: impact on the frequencies of 52 congenital anomaly types in three South American countries. Am J Med Genet A. 2010; 152A (10): 2444-58. doi: 10.1002/ajmg.a.33479
14. Botto LD, Lisi A, Robert-Gnansia E, Erickson JD, Vollset SE, Mastroiacovo P, et al. International retrospective cohort study of neural tube defects in relation to folic acid recommendations: are the recommendations working? BMJ. 2005; 330 (7491): 571. doi: 10.1136/bmj.38336.664352.82
15. Ulsenheimer MMM, Antoniuk SA, Santos LHCD, Ceccatto MP, Silveira AE, Ruiz AP, et al. Myelomeningocele: a Brazilian University Hospital experience. Arq Neuropsiquiatr. 2004; 62 (4): 963-8. doi: 10.1590/S0004-282X2004000600006
16. Faraji M, Ashrafzadeh F, Ariamanesh A, Faraji S. Surgical Outcome of Patients With Meningomyelocele Treated With a Team Approach. Neurosurg Q. 2006; 16 (2): 85-8. doi: 10.1097/00013414-200606000-00007
17. Althouse R, Wald N. Survival and handicap of infants with spina bifida. Arch Dis Child. 1980; 55 (11): 845-50. doi: 10.1136/adc.55.11.845
18. Bowman RM, McLone DG, Grant JA, Tomita T, Ito JA. Spina bifida outcome: a 25-year prospective. Pediatr Neurosurg. 2001; 34 (3): 114-20. doi: 10.1159/000056005
19. Piatt JH Jr. Treatment of myelomeningocele: a review of outcomes and continuing neurosurgical considerations among adults. J Neurosurg Pediatr. 2010; 6 (6): 515-25. doi: 10.3171/2010.9.PEDS10266
20. Oakeshott P, Reid F, Poulton A, Markus H, Whitaker RH, Hunt GM. Neurological level at birth predicts survival to the mid-40s and urological deaths in open spina bifida: a complete prospective cohort study. Dev Med Child Neurol. 2015; 57 (7): 634-8. doi: 10.1111/dmcn.12698
21. Talamonti G, D’Aliberti G, Collice M. Myelomeningocele: long-term neurosurgical treatment and follow-up in 202 patients. J Neurosurg. 2007 107 (5 Suppl): 368-86. doi: 10.3171/PED-07/11/368
22. Sutton M, Daly LE, Kirke PN. Survival and disability in a cohort of neural tube defect births in Dublin, Ireland. Birth Defects Res A Clin Mol Teratol. 2008; 82 (10): 701-9. doi: 10.1002/bdra.20498
23. Botto LD, Mulinare J, Erickson JD. Occurrence of congenital heart defects in relation to maternal mulitivitamin use. Am J Epidemiol. 2000; 151 (9): 878-84. doi: 10.1093/oxfordjournals.aje.a010291
24. Barboza-Arguello ML, Benavides-Lara A, Umaña L, Vargas-Leitón B. [Infant mortality from birth defects in Costa Rica, 1981–2010]. Rev Panam Salud Publica. 2013; 34 (5): 304-11. Spanish.
25. Tuli S, Tuli J, Drake J, Spears J. Predictors of death in pediatric patients requiring cerebrospinal fluid shunts. J Neurosurg. 2004; 100 (5 Suppl Pediatrics): 442-6. doi: 10.3171/ped.2004.100.5.0442
26. Charney EB, Melchionni JB, Antonucci DL. Ventriculitis in newborns with myelomeningocele. Am J Dis Child. 1991; 145 (3): 287-90. doi: 10.1001/archpedi.1991.02160030055020
27. Veenboer PW, Bosch JL, Asbeck FW, Kort LM. Upper and lower urinary tract outcomes in adult myelomeningocele patients: a systematic review. PLoS One. 2012; 7 (10): e48399. doi: 10.1371/journal.pone.0048399
28. McLone DG. Results of treatment of children born with a myelomeningocele. Clin Neurosurg. 1983; 30: 407-12.
29. Tubbs RS, Oakes WJ. Treatment and management of the Chiari II malformation: an evidence-based review of the literature. Childs Nerv Syst. 2004; 20 (6): 375-81. doi: 10.1007/s00381-004-0969-4
30. Salomão JF, Bellas AR, Leibinger RD, Barbosa AP, Brandão MA. [Symptomatic Chiari type II malformation]. Arq Neuropsiquiatr. 1998; 56 (1): 98-106. Portuguese. doi: 10.1590/S0004-282X1998000100016
31. Salomão JF, Leibinger RD, Carvalho JG, Pinheiro JA, Lucchesi GL, Bomfim V. [Follow-up of myelomeningocele patients in the outclinic of a pediatric hospital]. Arq Neuropsiquiatr. 1995; 53 (3A): 444-50. Portuguese. doi: 10.1590/S0004-282X1995000300013